Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Abbott Laboratories (NYSE:ABT)

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased $1,001–$15,000 of Abbott Laboratories stock on September 18 through a Bank of America trust account.
• Abbott reported quarterly revenue of $12.59 billion and earnings of $1.31 per share, exceeding analyst estimates; revenue rose 13% year over year. The company guided for 2026 earnings of $5.45–$5.60 per share.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $118.88. Abbott also declared a quarterly dividend of $0.63 per share, implying a 2.5% annual yield.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on September 18th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $102.71 on Wednesday. Abbott Laboratories has a one year low of $81.97 and a one year high of $133.34. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company has a 50 day moving average price of $106.08 and a 200 day moving average price of $98.27. The firm has a market capitalization of $177.72 billion, a price-to-earnings ratio of 33.24, a price-to-earnings-growth ratio of 1.89 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm posted $1.26 earnings per share. Abbott Laboratories's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories's payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ABT. Rothschild & Co Redburn raised Abbott Laboratories from a "neutral" rating to a "buy" rating and boosted their price target for the company from $119.00 to $127.00 in a research report on Friday, October 2nd. Weiss Ratings raised Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 18th. Wells Fargo & Company lifted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. Royal Bank Of Canada reiterated an "outperform" rating and set a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an "outperform" rating and a $121.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $118.88.

Institutional Trading of Abbott Laboratories

A number of institutional investors have recently added to or reduced their stakes in ABT. Copley Financial Group Inc. grew its position in Abbott Laboratories by 2.1% during the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker's stock valued at $556,000 after buying an additional 93 shares during the period. WealthTrust Axiom LLC raised its stake in Abbott Laboratories by 3.2% in the 4th quarter. WealthTrust Axiom LLC now owns 3,064 shares of the healthcare product maker's stock valued at $384,000 after acquiring an additional 94 shares during the period. St. Johns Investment Management Company LLC raised its stake in Abbott Laboratories by 1.0% in the 2nd quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker's stock valued at $895,000 after acquiring an additional 101 shares during the period. Davidson Investment Advisors lifted its holdings in Abbott Laboratories by 3.6% during the second quarter. Davidson Investment Advisors now owns 3,084 shares of the healthcare product maker's stock valued at $280,000 after purchasing an additional 106 shares during the last quarter. Finally, Kinloch Capital LLC lifted its holdings in Abbott Laboratories by 0.4% during the fourth quarter. Kinloch Capital LLC now owns 29,202 shares of the healthcare product maker's stock valued at $3,659,000 after purchasing an additional 111 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Abbott Laboratories

Abbott Laboratories NYSE: ABT is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott's medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.